While Takeda Pharmaceutical Co. Ltd. is "very pleased" with the recent deal to sell Xiidra to Novartis AG, "there will be more to come" as the Japanese firm continues to rationalize assets after the Shire PLC acquisition, CEO Christophe Weber says.
The deal for ex-Shire dry eye drug Xiidra (lifitegrast) is worth up to $5.3bn in total to Takeda, which has...








